NCT06841653Recruiting
A.I and Machine Learning Based Risk Prediction Model to Improve the Clinical Management of Endometrial Cancer.
A.I and Machine Learning Based Risk Prediction Model to Improve the Clinical Management of Endometrial Cancer: a Composite Approach Integrating the MultiOMics IMmune-IConographic Pattern (MOMIMIC Score) Towards Precision Oncology and Surgery.
Source: ClinicalTrials.gov · Last updated 24 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Prediction of preoperative endometrial biopsy: the evolution from hyperplasia to cancer, the prognosis and the risk of recurrence. Intelligence methods artificial risk will be used to redefine the current risk classes including our profile immuno-mutational to provide a more precise characterization and closer to the real prognosis of the patient.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 40 (estimated)
- First submitted
- 18 Feb 2025
- Start date
- 20 Jun 2024
- Primary completion date
- 20 Jun 2026
- Lead sponsor
- Regina Elena Cancer Institute
- Diseases
- Endometrial cancer
- NCT number
- NCT06841653
What you commit to
- Study type: Observational
- Planned participants: 40
- From 20 Jun 2024 to the primary completion date, 20 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- All exclusion criteria adopted in the surgical protocols will be applied to the study. In particular:
- Comorbidities not controlled with adequate medical therapy;
- Previous radiotherapy treatments of the pelvic region;
- Hormone therapies.
Other illness
- Infections of the endometrial cavity (pyometra);
- Synchronous cancer;
Other
- Neoadjuvant treatments;
Who the study is looking for
- Age \> 18 years;
- Histological diagnosis of endometrial hyperplasia, endometrioid adenocarcinoma of the endometrium, healthy endometrium in patients undergoing total hysterectomy for benign extra-endometrial disease;
- Written informed consent (to the study and data processing), for the party's patients only prospective and/or in follow-up) For the retrospective cohort: availability of samples adequately stored at the biobank of the Institute and availability of data relating to follow-up (at least 2 years)
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCCS National Cancer Institute "Regina Elena" Coordinator of this site? Confirm its status | Rome | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.